November 14, 2022
A genomic study of more than 200 people with the most common type of bladder cancer that has spread could help guide how the cancer would respond to immunotherapy.
August 30, 2021
Tracy Rose, MD, MPH, Matthew Milowsky, MD, and colleagues report that the regimen reduced the invasiveness of the cancer in 56% of patients in a phase II clinical trial.
August 16, 2021
William Kim, MD, and colleagues have published findings that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission in laboratory models.
July 27, 2021
Led by William Kim, MD, and colleagues, this research has important implications for patients who have not been offered immunotherapy because of their genetic profiles.
April 19, 2019
The idea was simple: find the faulty signals that drive cancerous growth in cells, and block them. But what University of North Carolina Lineberger Comprehensive Cancer Center researcher Pengda Liu, PhD, has discovered, when it comes to cancer, even straightforward concepts can become complicated. “When you find a target and inhibit it, you find the …
April 17, 2019
A study by University of North Carolina Lineberger Comprehensive Cancer Center researchers helps explain how tumors recruit blood vessels that provide fuel for their growth as well as an avenue for the tumors to spread. In the journal Oncogene, the researchers also reported they built on these findings to uncover a potential treatment strategy to …
July 19, 2018
In a study published in the journal Science, researchers led by UNC Lineberger's Qing Zhang, PhD, suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer.
